Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell–Redirecting Immunotherapies
Authors:
- Marios PapadimitriouMPMarios Papadimitriou
- Sungwoo AhnSASungwoo Ahn
- Benjamin T. DiamondBDBenjamin T. Diamond
- Holly LeeHLHolly Lee
- John B. McIntyreJMJohn B. McIntyre
- Marietta TrugerMTMarietta Truger
- Michael A. DuranteMDMichael A. Durante
- Bachisio ZicchedduBZBachisio Ziccheddu
- Katalin OszKOKatalin Osz
- Ola LandgrenOLOla Landgren
- Leo RascheLeo Rasche
- Nizar J. BahlisNBNizar J. Bahlis
- 4 September 2025
- journal article
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 6 (6) , 572-579
Abstract
Genomic antigen loss is a recurring mechanism of resistance to chimeric antigen receptor T-cell (CAR-T) and T-cell engagers (TCE) in relapsed/refractory multiple myeloma (RRMM). Yet, it remains unclear whether these events are acquired under treatment or merely selected from preexisting, undetectable clones. By leveraging chemotherapy mutational signatures as temporal barcodes within whole-genome sequencing data, we could time genomic antigen escape in 4 of 11 patients with RRMM. In all cases, the biallelic loss was driven by genomic events acquired after exposure to BCMA- and GPCR5D-targeted CAR-T/TCE and not present at baseline. Longitudinal digital PCR analysis corroborated that resistance mutations were undetectable at therapy initiation but emerged preceding relapse. Among 752 newly diagnosed patients, only 2.7% and 9% had monoallelic inactivation of TNFRSF17 and GPCR5D, respectively, with no biallelic loss. Our findings suggest limited utility of mutational screening prior to CAR-T/TCE while underscoring the importance of dynamic surveillance during therapy. Significance: Multiple myeloma has been demonstrated to recurrently develop resistance to T-cell redirection via genomic antigen escape. By leveraging chemotherapy mutational signatures, we demonstrate that somatic antigen-escape mechanisms are uniformly acquired following treatment initiation and not selected from among preexisting clones, emphasizing the importance of dynamic longitudinal surveillance for their emergence. See related commentary by Kauer et al., p. 532Keywords
All Related Versions
Funding Information
- National Institutes of Health (P30 CA 008748)
- National Institutes of Health (P30 CA 240139)
This publication has 25 references indexed in Scilit:
- Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myelomaNature Communications, 2025
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory statesNature Communications, 2022
- Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 studyThe Lancet, 2021
- Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trialThe Lancet Haematology, 2021
- The mutagenic impact of melphalan in multiple myelomaLeukemia, 2021
- Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myelomaNature Communications, 2021
- Accelerated single cell seeding in relapsed multiple myelomaNature Communications, 2020
- Timing the initiation of multiple myelomaNature Communications, 2020
- Reconstructing the evolutionary history of multiple myelomaBest Practice & Research Clinical Haematology, 2020
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencingNature Communications, 2017